Aim Bulletin
Deltex launches new system in UK, EU markets
Oesophageal monitoring technology specialist Deltex Medical Group announced the launch of its next-generation ‘TrueVue’ system in the UK and the EU on Monday.
Impax AuM falls 1pc over third quarter
Impax Asset Management updated the market on the development of its assets under discretionary and advisory management (AuM) for its third quarter on Monday.
ITM Power launching new Germany hub
Electrolyser specialist ITM Power is expanding its presence in Germany, it announced on Monday, with the establishment of ITM Power Germany.
Hutchmed launches new phase one study in China
Biopharmaceutical company Hutchmed China announced the launch of a phase one study in China for HMPL-415 on Monday - an investigational selective allosteric inhibitor that targeted Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2).
Cordel extends contract with Australian Rail Track Corporation
Cordel Group announced the extension of its existing clearances contract with the Australian Rail Track Corporation (ARTC) on Monday, until 31 August 2024.
MaxCyte signs licence deal with Vittoria Biotherapeutics
MaxCyte announced a strategic platform licence agreement with Vittoria Biotherapeutics on Monday, granting Vittoria non-exclusive clinical and commercial rights to use MaxCyte's ‘Flow Electroporation’ technology and ‘ExPERT’ platform.
WANdisco renews contract with Tesco Stores
Data specialist WANdisco announced the renewal of its software support and maintenance contract with Tesco Stores on Monday.
OnTheMarket cautious after year of solid growth
Property marketing platform OnTheMarket reported significant growth in revenue, EBITDA, operating profit, and profit before tax in its full-year results on Monday.